Abstract：
UNASSIGNED: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. Its prevalence has increased due to worldwide populations that are aging in combination with the growing incidence of risk factors associated. Recent advances in our understanding of AF pathophysiology and the identification of nodal players involved in AF-promoting atrial remodeling highlights potential opportunities for new therapeutic approaches.
UNASSIGNED: This detailed review summarizes recent developments in the field antiarrhythmic drugs in the field AF.
UNASSIGNED: The current situation is far than optimal. Despite clear unmet needs in drug development in the field of AF treatment, the current development of new drugs is absent. The need for a molecule with absence of cardiac and non-cardiac toxicity in the short and long term is a limitation in the field. Improvement in the understanding of AF genetics, pathophysiology, molecular alterations, big data and artificial intelligence with the objective to provide a personalized AF treatment will be the cornerstone of AF treatment in the coming years.
UNASSIGNED: This detailed review summarizes recent developments in the field antiarrhythmic drugs in the field AF.
UNASSIGNED: The current situation is far than optimal. Despite clear unmet needs in drug development in the field of AF treatment, the current development of new drugs is absent. The need for a molecule with absence of cardiac and non-cardiac toxicity in the short and long term is a limitation in the field. Improvement in the understanding of AF genetics, pathophysiology, molecular alterations, big data and artificial intelligence with the objective to provide a personalized AF treatment will be the cornerstone of AF treatment in the coming years.
摘要：
■心房颤动（AF）是最常见的心律失常类型。由于全球人口老龄化以及相关危险因素的发病率增加，其患病率增加。我们对AF病理生理学的理解以及与AF促进心房重构有关的淋巴结参与者的识别的最新进展突出了新的治疗方法的潜在机会。
■这篇详细的综述总结了房颤领域抗心律失常药物的最新进展。
■目前的情况远非最佳。尽管在AF治疗领域的药物开发中存在明显的未满足的需求，目前缺乏新药的开发。对短期和长期不存在心脏和非心脏毒性的分子的需要是本领域的限制。提高对AF遗传学的理解，病理生理学,分子改变,以提供个性化AF治疗为目标的大数据和人工智能将是未来几年AF治疗的基石。
■这篇详细的综述总结了房颤领域抗心律失常药物的最新进展。
■目前的情况远非最佳。尽管在AF治疗领域的药物开发中存在明显的未满足的需求，目前缺乏新药的开发。对短期和长期不存在心脏和非心脏毒性的分子的需要是本领域的限制。提高对AF遗传学的理解，病理生理学,分子改变,以提供个性化AF治疗为目标的大数据和人工智能将是未来几年AF治疗的基石。
